中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2013年
6期
633-635
,共3页
饶远权%刘杏娥%江皓%王廷祥
饒遠權%劉杏娥%江皓%王廷祥
요원권%류행아%강호%왕정상
肿瘤,血管组织%胃肠肿瘤
腫瘤,血管組織%胃腸腫瘤
종류,혈관조직%위장종류
Neoplasrns,vasculartissue%Gastrointestinal neoplasms
目的 观察贝伐珠单抗联合化疗治疗老年胃肠肿瘤的近期疗效和不良反应. 方法 对64例老年胃肠肿瘤患者化疗联合贝伐单抗治疗的临床资料进行分析,临床随机分为观察组和对照组各33例,两组患者均采用希罗达联合奥沙利铂(XELOX)方案进行治疗,每21周为1周期.观察组额外使用贝伐珠单抗7.5 mg/kg,周期同观察组.根据WHO近期疗效标准和WHO抗癌药物急性与亚急性不良反应表现和分度标准进行客观疗效评价和不良反应评定. 结果 64例老年胃肠肿瘤患者中,观察组总有效率68.8％,疾病控制率为87.5％；对照组总有效率43.8％,疾病控制为78.1％.观察组患者不良反应中,白细胞减少、血红蛋白下降、消化道反应的发生率均小于对照组,血小板减少的发生率观察组高于对照组,但差异均无统计学意义.观察组中无Ⅳ期不良反应发生.结论 贝伐珠单抗联合化疗治疗老年胃肠肿瘤患者近期疗效明显,不良反应患者可耐受,安全有效,适合临床推广使用.
目的 觀察貝伐珠單抗聯閤化療治療老年胃腸腫瘤的近期療效和不良反應. 方法 對64例老年胃腸腫瘤患者化療聯閤貝伐單抗治療的臨床資料進行分析,臨床隨機分為觀察組和對照組各33例,兩組患者均採用希囉達聯閤奧沙利鉑(XELOX)方案進行治療,每21週為1週期.觀察組額外使用貝伐珠單抗7.5 mg/kg,週期同觀察組.根據WHO近期療效標準和WHO抗癌藥物急性與亞急性不良反應錶現和分度標準進行客觀療效評價和不良反應評定. 結果 64例老年胃腸腫瘤患者中,觀察組總有效率68.8％,疾病控製率為87.5％；對照組總有效率43.8％,疾病控製為78.1％.觀察組患者不良反應中,白細胞減少、血紅蛋白下降、消化道反應的髮生率均小于對照組,血小闆減少的髮生率觀察組高于對照組,但差異均無統計學意義.觀察組中無Ⅳ期不良反應髮生.結論 貝伐珠單抗聯閤化療治療老年胃腸腫瘤患者近期療效明顯,不良反應患者可耐受,安全有效,適閤臨床推廣使用.
목적 관찰패벌주단항연합화료치료노년위장종류적근기료효화불량반응. 방법 대64례노년위장종류환자화료연합패벌단항치료적림상자료진행분석,림상수궤분위관찰조화대조조각33례,량조환자균채용희라체연합오사리박(XELOX)방안진행치료,매21주위1주기.관찰조액외사용패벌주단항7.5 mg/kg,주기동관찰조.근거WHO근기료효표준화WHO항암약물급성여아급성불량반응표현화분도표준진행객관료효평개화불량반응평정. 결과 64례노년위장종류환자중,관찰조총유효솔68.8％,질병공제솔위87.5％；대조조총유효솔43.8％,질병공제위78.1％.관찰조환자불량반응중,백세포감소、혈홍단백하강、소화도반응적발생솔균소우대조조,혈소판감소적발생솔관찰조고우대조조,단차이균무통계학의의.관찰조중무Ⅳ기불량반응발생.결론 패벌주단항연합화료치료노년위장종류환자근기료효명현,불량반응환자가내수,안전유효,괄합림상추엄사용.
Objective To investigate the clinical efficacy and toxicity of bevacizumab combined with chemotherapy in elderly patients with gastrointestinal neoplasms.Methods A total of 64 elderly patients with gastrointestinal neoplasms were selected.The clinical data of patients treated with chemotherapy or chemotherapy plus bevacizumab were analyzed.Patients were randomly divided into the observation group and the control group (n=32,each).The observation group was treated with bevacizumab (7.5 mg/kg) in combination with XELOX (OXA+Xeloda),and the control group was treated with XELOX only (21 weeks as a cycle).The clinical efficacy and toxicity of bevacizumab were evaluated according to WHO short-term efficacy standards and standards of anticancer drugs in acute or subacute adverse reactions.Results In observation group,complete remission was found in 4 cases,partial response in 18 cases,stable disease in 6 cases,progressive disease in 4 cases,and the total efficiency was 68.8％.In control group,partial response was found in 14 cases,stable disease in 11 cases,progressive disease in 7 cases,and the total efficiency was 43.8％.The incidences of leucopenia,hemoglobin desaturation and gastrointestinal reactions were lower and the incidence of thrombocytopenia was higher in observation group than in control group,which had no significant differences between the 2 groups.Phase Ⅳ toxicity was not found in observation group.Conclusions Bevacizumab combined with chemotherapy is safe and effective for elderly patients with gastrointestinal neoplasms.Most patients can tolerate the side effects.It is worth promoting in clinical medicine.
